A pharmacist who enters into a common pharmacy practice agreement must provide the board with a copy of the signed agreement before the agreement can be implemented. The Board of Directors is currently developing and reviewing proposed rules, in accordance with the new legislation, that will transpose and expand the requirements for community pharmacy practice agreements, as well as the review and treatment of minor and non-chronic sanitary conditions, in accordance with a written protocol containing a monitoring provision. Upon approval, these rules will be published in the Florida Administrative Code and are expected to come into effect on July 1, 2020. On June 25, 2020, the Committee`s Joint Committee on Internal Regulation has a meeting to review the proposed rules. A project is available on the map`s website and is summarized below. The bill amends many practical laws to streamline regulation and increase efficiency. The bill contains numerous updates and changes to health programs and professions regulated by boards of directors and the Ministry of Health (DOH): an advisory pharmacist can only provide services to the patients of the physician with whom the advisory pharmacist has a written cooperation agreement. The bill requires both the advisory pharmacist and the physician to keep a copy of the cooperation agreement and make it available upon request or during an inspection. The bill also requires the consultant pharmacist to keep all drug, patient care and quality assurance notes. The bill authorizes a pharmacist to enter into a Collaborative Pharmacy Practice Agreement (ACP) with a physician to treat chronic diseases when the pharmacist completes certain qualifications. A CPPA must meet certain conditions and indicate sanitary conditions, treatments and tests submitted to the CPPA. The bill prohibits a cooperating pharmacist from initiating or prescribing a controlled substance or modifying or discontinuing medications prescribed by a physician who does not have a CPPA with the pharmacist.
Florida is considering increasing patient access to care, particularly because of the COVID 19 pandemic and the expected increase in the number of cases. Recognizing the accessibility of pharmacies, Florida now allows certain qualified pharmacists, testing, screening and treatment of non-chronic diseases and specific treatment of certain chronic diseases. On March 11, 2020, the Florida legislature passed CS/HB 389 (Law). The Law: 1) authorizes qualified pharmacists to provide specific services to patients with certain chronic diseases as part of a community pharmacy practice agreement (a “collaboration agreement”) with a patient`s treating physician; 2) allows pharmacists with medical nursing physicians, in accordance with written agreements, to test, examine and treat patients for “minor and non-chronic health conditions.” Section 465.1865, Florida Statutes, provides that a pharmacist who wishes to practice under a Community Practice Agreement must meet the following requirements: Legislation prohibits the modification or hiring of drugs by pharmacists prescribed by a physician with whom they do not have a community pharmacy practice agreement, and a physician cannot delegate the power to initiate certain controlled substances or prescribe a pharmacist.